PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

TB-500 — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Analysis of the product sold as TB-500 identified the N-terminally acetylated 17-23 fragment of human thymosin beta 4, Ac-LKKTETQ. · pmid:22962027

Mechanism

The LKKTETQ sequence lies in thymosin beta 4's central actin-binding domain, and short peptides containing it promoted angiogenesis, wound healing and cell migration. · pmid:20179146

Identity

PubChem CID 62707662: Unii-qhk6Z47gtg, C38H68N10O14, 889.0 g/mol. · pubchem:62707662

CAS registry number 885340-08-9. · pubchem:62707662

IUPAC name: (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid. · pubchem:62707662

Where the evidence actually sits

Preclinical only50%
Unknown50%

Proportion of the 2 claims about TB-500 standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Biological activities of thymosin beta4 defined by active sites in short peptide sequences. (2010) · preclinicalSynthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. (2012) · unknown20102012

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for TB-500 yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work
    • Biological activities of thymosin beta4 defined by active sites in short peptide sequences. · pmid 20179146 · 2010

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.